-
1 Comment
From a valuation standpoint, the stock is 92.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2573.2.
Based on the above factors, Seer, Inc gets an overall score of 0/5.
ISIN | US81578P1066 |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
CurrencyCode | USD |
Exchange | NASDAQ |
PE Ratio | None |
---|---|
Target Price | 8.67 |
Beta | 1.26 |
Dividend Yield | 0.0% |
Market Cap | 266M |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SEER using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024